Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

Gut

Volumn 43, Issue 2, 1998, Pages 203-209

  Noguchi, M ^a   Hiwatashi, N ^a   Liu, Z ^a   Toyota, T ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Crohn's disease; Inflammation; Mucosal immunology; Soluble TNF receptor; Tumour necrosis factor; Ulcerative colitis

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; MALE; ORGAN CULTURE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0031853981     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.2.203     Document Type: Article

References (50)

1. Sartor RH. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and exprimental intestinal inflammation. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease, 4th edn. Baltimore: Williams & Wilkins, 1995:96-124.
2. Van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-9.
3. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;3(suppl):1160-9.
4. Beutler B, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985;13(suppl):3972-7.
5. Torimoto K, Sato N, Okubo M, et al. Development of multiple necrotizing enteritis induced by a tumor necrosis factor-like cytokine from lipopolysaccharide-stimulated peritoneal macrophages in rats. Am J Pathol 1990;137: 1103-11.
6. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
7. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
8. Van Dullemen HM, van Deventer SHJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
9. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997;349:521-4.
10. Targan SR, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
11. Braegger CP, Nicholls S, Murch SH, et al. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
12. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17.
13. Hyams JS, Treem WR, Eddy E, et al. Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991;12:233-6.
14. Isaacs KL, Sartor B, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
15. Van Hees PA, Van Elteran PH, Van Lier JH, et al. An index of inflammatory activity in patients with Crohn's disease. Gut 1980;21:279-86.
16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: a final report on a therapeutic trial. BMJ 1955;2:1041-4.
17. Eastwood GL, Trier TS. Organ culture of human rectal mucosa. Gastroenterology 1973;64:375-82.
18. Bull DM, Bookman MA. Isolation and functional characterization of human intestinal mucosal lymphoid cells. J Clin Invest 1977;59:966-74.
19. Noguchi M, Hiwatashi N, Liu Z, et al. Enhanced interferon-γ production and B7 2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. J Gastroenterol 1995;30(suppl 8):52-5.
20. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
21. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
22. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106:1455-66.
23. Kaplan D. Autocrine secretion and the physiological concentration of cytokines. Immunol Today 1996;17:303-4.
24. Bazil V. Physiological enzymatic cleavage of leukocyte membrane molecules. Immunol Today 1995;16:135-40.
25. Black R, Rauch CT, Kozlosky CJ, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997;385:729-33.
26. Eigler A, Sinha B, Hartmann G, et al. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997;18:487-91.
27. Takasuka K, Tokunaga T, Akagawa KS. Preexposure of macrophages to low doses of lipopolysaccharide inhibits the expression of tumor necrosis factor-α mRNA but not IL-1β mRNA. J Immunol 1991;146:3824-30.
28. Rugtveit J, Nilsen EM, Bakka A, et al. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997;112:1493-505.
29. Leeuwenberg JFM, Dentener MA, Buurman WA. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. J Immunol 1994;152:5070-6.
30. Foley N, Lambert C, McNicol M, et al. An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin Exp Immunol 1990;80:395-9.
31. Bouma G, Pool MO, Scharenberg JGM, et al. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995;30:1095-100.
32. Monajemi H, Meenan J, Lamping R, et al. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. Gastroenterology 1996;110:733-9.
33. Ni J, Porter AG, Hollander D. β7 integrins and other cell adhesion molecules are differentially expressed and modulated by TNF-β in different lymphocyte populations. Cell Immunol 1995;161:166-72.
34. Banks TA, Rouse BT, Kerley MK, et al. Lymphotoxin-α-deficient mice. J Immunol 1995;155:1685-93.
35. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-α, interleukin-1β and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39: 684-9.
36. Mullin JM, Snock KV. Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. Cancer Res 1990;50:2172-6.
37. Mahraoui L, Heyman M, Plique O, et al. Apical effect of diosmectite on damage to the intestinal barrier induced by tumour necrosis factor-α. Gut 1997;40:339-43.
38. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-9.
39. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4.
40. Ghosh S, Ferguson A. Mucosal immunology research design should address not just cytokines and cells, but also clinical data and controls. Clin Exp Immunol 1994;96:377-8.
41. Cellier C, Sahmond T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut 1994;35:231-5.
42. Herve BP, Flesch M, Tierghien P, et al. Phase I II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992;79:3362-8.
43. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
44. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
45. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997;350:1445-6.
46. Lanz M, Thysell H, Nilsson E, Olsson I. On the binding of tumor necrosis factor to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991; 88:2026-31.
47. Gaffney PR, O'Leary JJ, Doyle CT, et al. Response to heparin in patients with ulcerative colitis. Lancet 1991;337: 238-9.
48. Stronkhorst A, Jansen J, ten Berge RJM, et al. Functional downregulation and TNF receptor shedding by T-cells following antiCD4 treatment of patients with Crohn's disease [abstract]. Gastroenterology 1994;106:779.
49. Korner H, Goodsall AL, Lemckert FA, et al. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc. Natl Acad Sci USA 1995;92:11066-70.
50. Van deventer SJH. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.